Table 2 Patient characteristics (group B).

M-spike, serum or urine myeloma paraprotein quantification by electrophoresis; Std., standard risk [(not 17p/p53 altered or t(4;14), t(14;16)]; quant., quantification.

IDAge/GR-ISSCytogenetic
risk
No. of
prior lines
Time to T cells
from last
therapy
Persistent or
progressive
disease
Prior Imid/
PI/MoAb?
No. of ASCTs
(time to
progression
after ASCT, if
applicable)
Preinfusion
marrow
involvement
DLNo. of
infusions
TAA expression
at baseline
153/MIIStd.24 moPersistentN/Y/N110%12MAGE,
NY-ESO-1,
PRAME, SSX2,
Survivin
240/MIIStd.42 moPersistentY/Y/N2 (6 mo)20%18MAGE, PRAME
365/FIIt(4;14)52 moProgressiveY/Y/N2 (26 mo)15%14PRAME, Survivin
576/MIIStd.22 moPersistentN/Y/N120%17PRAME,
NY-ESO-1,
MAGE, SSX2,
Survivin
1069/FIStd.43 moPersistentY/Y/N110%28MAGE,
NY-ESO-1,
PRAME, Survivin
1331/FIIStd.14 moPersistentN/Y/N04%22MAGE,
NY-ESO-1,
PRAME, SSX2
1447/MIIStd.34 moProgressiveY/Y/N1 (6 mo)0%23MAGE, PRAME,
Survivin
1570/MUnknownUnknown100.5 moProgressiveY/Y/Y180%33Unavailable
1744/FIIIHetero-Tp53
mutation (not
quant.)
31 moPersistentY/Y/N10% (M-spike
increasing:
0.4 g/dl)
34MAGE, NY-ESO-1,
PRAME, SSX2,
Survivin
2057/MIStd.90.5 moProgressiveY/Y/Y2 (18 mo & 11 mo)5%32Unavailable
2366/MII21%
heterozygous
17pdel
30.5 moPersistentY/Y/N1 (6 mo)0% (M spike
0.1 g/dl and free
kappa rising:
26 from 18 one
month prior)
32Unavailable
2448/FIIStd.91 moPersistentY/Y/Y2 (26 mo & 18 mo)0% (light
chain only,
free kappa
rising: 88.9
from
56.2 5 weeks
prior)
32Unavailable